Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 590.69M | 560.23M | 522.75M | 481.30M | 442.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 590.69M | 560.23M | 522.75M | 481.30M | 442.59M |
| Cost of Revenue | 1.11B | 1.11B | 1.06B | 1.05B | 1.04B |
| Gross Profit | -522.31M | -554.35M | -537.58M | -568.99M | -599.78M |
| SG&A Expenses | 331.25M | 321.61M | 315.95M | 310.51M | 311.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.10B | 1.10B | 1.06B | 1.03B | 1.02B |
| Operating Income | -513.57M | -535.97M | -535.74M | -548.85M | -580.45M |
| Income Before Tax | -547.13M | -567.59M | -561.07M | -586.86M | -615.22M |
| Income Tax Expenses | 2.45M | 1.60M | -2.09M | -1.74M | -1.87M |
| Earnings from Continuing Operations | -549.58 | -569.18 | -558.99 | -585.12 | -613.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -549.58M | -569.18M | -558.99M | -585.12M | -613.35M |
| EBIT | -513.57M | -535.97M | -535.74M | -548.85M | -580.45M |
| EBITDA | -477.88M | -500.43M | -501.06M | -515.74M | -550.84M |
| EPS Basic | -5.88 | -6.34 | -6.46 | -7.29 | -8.03 |
| Normalized Basic EPS | -3.62 | -3.94 | -4.07 | -4.57 | -5.06 |
| EPS Diluted | -5.88 | -6.34 | -6.46 | -7.29 | -8.03 |
| Normalized Diluted EPS | -3.62 | -3.94 | -4.07 | -4.57 | -5.06 |
| Average Basic Shares Outstanding | 374.04M | 362.04M | 347.48M | 323.65M | 307.97M |
| Average Diluted Shares Outstanding | 374.04M | 362.04M | 347.48M | 323.65M | 307.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |